20 June 2016

Circassia sinks as key allergy drug fails PhIII

One of the jewels in the U.K. biotech crown became a lot duller today as Circassia (LON:CIR) saw its shares fall 64% by 12 pm BST after its key allergy drug failed to best placebo. The late-stage trial for its investigational cat allergy immunotherapy was aiming to not just alleviate symptoms, but also treat the heart of the condition by helping patients’ immune systems tolerate the allergens. But in the Phase III study, a major and marked placebo effect made the high-profile biotech miss its trial’s primary endpoint, as its med was not significantly different from placebo. Source: Fierce Biotech 20/6/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).